Preclinical Childhood Tumor Models: Drug Efficacy Biomarker Identification and Validation

Over the past 35 years, cure rates for pediatric cancers have increased dramatically. However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. Consequently, novel, less genotoxic, agents are...

Full description

Bibliographic Details
Main Authors: Brian eGeier, Dias eKurmashev, Raushan T Kurmasheva, Peter J Houghton
Format: Article
Language:English
Published: Frontiers Media S.A. 2015-08-01
Series:Frontiers in Oncology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00193/full
id doaj-4adea9f5f06c414a9408907418bdc020
record_format Article
spelling doaj-4adea9f5f06c414a9408907418bdc0202020-11-24T20:49:05ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2015-08-01510.3389/fonc.2015.00193150307Preclinical Childhood Tumor Models: Drug Efficacy Biomarker Identification and ValidationBrian eGeier0Dias eKurmashev1Raushan T Kurmasheva2Peter J Houghton3Nationwide Children's HospitalUniversity of TexasUniversity of TexasUniversity of TexasOver the past 35 years, cure rates for pediatric cancers have increased dramatically. However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. Consequently, novel, less genotoxic, agents are being sought to complement existing treatments. Here we discuss preclinical human tumor xenograft models of pediatric cancers that may be used practically to identify novel agents, and ‘omics’ approaches to identifying biomarkers that may identify sensitive and resistant tumors to these agents.http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00193/fullData Miningbioinformaticsxenograftschildhood cancerPreclinical PharmacologyHuman tumor xenografts; drug sensitivity; expression profiling; copy number variation; elastic net; long-intergenic non-coding RNA’s
collection DOAJ
language English
format Article
sources DOAJ
author Brian eGeier
Dias eKurmashev
Raushan T Kurmasheva
Peter J Houghton
spellingShingle Brian eGeier
Dias eKurmashev
Raushan T Kurmasheva
Peter J Houghton
Preclinical Childhood Tumor Models: Drug Efficacy Biomarker Identification and Validation
Frontiers in Oncology
Data Mining
bioinformatics
xenografts
childhood cancer
Preclinical Pharmacology
Human tumor xenografts; drug sensitivity; expression profiling; copy number variation; elastic net; long-intergenic non-coding RNA’s
author_facet Brian eGeier
Dias eKurmashev
Raushan T Kurmasheva
Peter J Houghton
author_sort Brian eGeier
title Preclinical Childhood Tumor Models: Drug Efficacy Biomarker Identification and Validation
title_short Preclinical Childhood Tumor Models: Drug Efficacy Biomarker Identification and Validation
title_full Preclinical Childhood Tumor Models: Drug Efficacy Biomarker Identification and Validation
title_fullStr Preclinical Childhood Tumor Models: Drug Efficacy Biomarker Identification and Validation
title_full_unstemmed Preclinical Childhood Tumor Models: Drug Efficacy Biomarker Identification and Validation
title_sort preclinical childhood tumor models: drug efficacy biomarker identification and validation
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2015-08-01
description Over the past 35 years, cure rates for pediatric cancers have increased dramatically. However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. Consequently, novel, less genotoxic, agents are being sought to complement existing treatments. Here we discuss preclinical human tumor xenograft models of pediatric cancers that may be used practically to identify novel agents, and ‘omics’ approaches to identifying biomarkers that may identify sensitive and resistant tumors to these agents.
topic Data Mining
bioinformatics
xenografts
childhood cancer
Preclinical Pharmacology
Human tumor xenografts; drug sensitivity; expression profiling; copy number variation; elastic net; long-intergenic non-coding RNA’s
url http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00193/full
work_keys_str_mv AT brianegeier preclinicalchildhoodtumormodelsdrugefficacybiomarkeridentificationandvalidation
AT diasekurmashev preclinicalchildhoodtumormodelsdrugefficacybiomarkeridentificationandvalidation
AT raushantkurmasheva preclinicalchildhoodtumormodelsdrugefficacybiomarkeridentificationandvalidation
AT peterjhoughton preclinicalchildhoodtumormodelsdrugefficacybiomarkeridentificationandvalidation
_version_ 1716806807826989056